Search results for "V2"

showing 10 items of 446 documents

"Table 17" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential $v_{2}$ of muons from heavy-flavour decays extracted with Lee-Yang zeros (Sum) method.

PB PB --> MUON XInclusive2760.0Physics::Instrumentation and DetectorsHigh Energy Physics::LatticeHigh Energy Physics::PhenomenologyHigh Energy Physics::ExperimentV2{SP}(PT) OF HEAVY FLAVOUR DECAY MUONSMuon production
researchProduct

"Table 9" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with Lee-Yang zeros (Prod) method.

PB PB --> MUON XInclusive2760.0Physics::Instrumentation and DetectorsINCLUSIVE MUON V2{LYZ-PROD}(PT)Muon production
researchProduct

"Table 8" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with Lee-Yang zeros (Sum) method.

PB PB --> MUON XInclusive2760.0Physics::Instrumentation and DetectorsINCLUSIVE MUON V2{LYZ-SUM}(PT)Muon production
researchProduct

"Table 6" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with two-particle cumulants method.

PB PB --> MUON XInclusive2760.0Physics::Instrumentation and DetectorsPhysics::Accelerator PhysicsHigh Energy Physics::ExperimentINCLUSIVE MUON V2{2}(PT)Muon production
researchProduct

"Table 1" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with scalar product method.

PB PB --> MUON XInclusiveGeneral Relativity and Quantum Cosmology2760.0Physics::Instrumentation and DetectorsINCLUSIVE MUON V2{SP}(PT)Physics::Accelerator PhysicsHigh Energy Physics::ExperimentMuon production
researchProduct

"Table 3" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with scalar product method.

PB PB --> MUON XInclusiveGeneral Relativity and Quantum Cosmology2760.0Physics::Instrumentation and DetectorsINCLUSIVE MUON V2{SP}(PT)Physics::Accelerator PhysicsHigh Energy Physics::ExperimentMuon production
researchProduct

"Table 5" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with scalar product method.

PB PB --> MUON XInclusiveGeneral Relativity and Quantum Cosmology2760.0Physics::Instrumentation and DetectorsINCLUSIVE MUON V2{SP}(PT)Physics::Accelerator PhysicsHigh Energy Physics::ExperimentMuon production
researchProduct

"Table 7" of "Elliptic flow of muons from heavy-flavour hadron decays at forward rapidity in Pb-Pb collisions at $\sqrt{s_{\rm NN}}=2.76$ TeV"

2015

pT-differential inclusive muon $v_{2}$ extracted with four-particle cumulants method.

PB PB --> MUON XInclusiveINCLUSIVE MUON V2{4}(PT)2760.0Physics::Instrumentation and DetectorsPhysics::Accelerator PhysicsHigh Energy Physics::ExperimentMuon production
researchProduct

An international perspective on hospitalized patients with viral community-acquired pneumonia

2019

Background Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results 553 (14.9%) patients with CAP underwent nasal swab. Viral CA…

PNEUMONIAMaleMultivariate analysisInternationalityPCV13 pneumococcal conjugate vaccineDatabases FactualHospitalized patientsmedicine.medical_treatmentvirusesCAD coronary artery diseaseTesting030204 cardiovascular system & hematologyMRSA methicillin resistant Staphylococcus aureusPneumònia adquirida a la comunitatRT-PCR reverse transcriptase polymerase chain reactionchemistry.chemical_compound0302 clinical medicineCommunity-acquired pneumoniaTaverne80 and overCommunity-Acquired InfectionViral030212 general & internal medicineProspective StudiesAged 80 and overRIDT rapid influenza diagnostic testCAP community-acquired pneumoniaRSV Respiratory Syncytial virusMiddle AgedICU intensive care unitCommunity-Acquired InfectionsHospitalizationNasal SwabInfectious diseasesFemaleViral swabHumanOseltamivirmedicine.medical_specialtyLogistic ModelCommunity-acquired pneumoniaViral pneumoniaCommunity acquired pneumonia; Influenza; Oseltamivir; Testing; Viral pneumonia; Viral swab; Aged; Aged 80 and over; Antiviral Agents; Community-Acquired Infections; Cross-Sectional Studies; Databases Factual; Female; Hospitalization; Humans; Influenza Human; Internationality; Logistic Models; Male; Medication Adherence; Middle Aged; Oseltamivir; Pneumonia Viral; Prospective StudiesPneumonia ViralAdmissionSettore MED/10 - Malattie Dell'Apparato RespiratorioInfluenzavirusAntiviral AgentsVirusArticleMedication AdherenceHMPV human MetapneumovirusDatabases03 medical and health sciencesLRTI lower respiratory tract infectionOseltamivirInternal medicineInfluenza HumanInternal MedicinemedicineInfluenza virusesHumansHIV Human Immunodeficiency virusPPSV23 pneumococcal polysaccharide vaccineIn patientFactualAgedMechanical ventilationAntiviral AgentCross-Sectional Studiebusiness.industryFEV1 forced expiratory volume in one secondGLIMP global initiative for methicillin-resistant Staphylococcus aureus pneumoniaESBL extended-spectrum beta-lactamasesPneumoniamedicine.diseaseInfluenzaCommunity acquired pneumoniaCI confidence intervalOR odds ratioCross-Sectional StudiesLogistic ModelschemistryCOPD chronic obstructive pulmonary diseasebusinessCommunity acquired pneumonia ; Influenza ; Oseltamivir ; Testing ; Viral pneumonia ; Viral swab
researchProduct

Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature

2021

Kawasaki disease (KD) is a vasculitis of unknown origin of small and medium caliber blood vessels, especially involving coronary arteries and is the leading cause of acquired heart disease in childhood in developed countries. Although rarely, it can recur: most recurrences occur within 2 years of the initial episode. No data are available on incidence of recurrent KD in Europe and multiple recurrences are rarely seen. We reviewed the medical literature on Kawasaki disease recurrence and reported a new case of Kawasaki disease recurrence in a child with SARS-CoV-2 infection. We believe that in our case SARS Cov2 acted as a trigger capable to determine, in a genetically susceptible individual…

Pediatricsmedicine.medical_specialtyHeart diseaseSettore MED/17 - Malattie InfettiveDiseaseReviewMucocutaneous Lymph Node SyndromePediatricsRJ1-57003 medical and health sciences0302 clinical medicineRecurrence030225 pediatricsSars-Cov2EpidemiologymedicineHumans030212 general & internal medicineskin and connective tissue diseasesChildPandemicsbusiness.industrySARS-CoV-2Incidence (epidemiology)IncidenceInfantmedicine.diseaseSars-Cov2Coronary arteriesmedicine.anatomical_structureRecurrent Kawasaki diseaseChild PreschoolKawasaki diseaseKawasaki disease recurrenceVasculitisbusinessCovid-19Medical literature
researchProduct